Companies: 48,687 Total Market Cap: 127170027423520.77

Shin Nippon Biomedical Laboratories, Ltd.

TYO-2395
Healthcare Medical - Diagnostics & Research
Rank #14001
Market Cap 445.73 M
Volume 5,615.16
Price 10.71
Change (%) 0.77%
Country or region Japan Japan

Shin Nippon Biomedical Laboratories, Ltd.'s latest marketcap:

445.73 M

As of May 4, 2025, Shin Nippon Biomedical Laboratories, Ltd.'s market capitalization has reached $445.73 M. According to our data, Shin Nippon Biomedical Laboratories, Ltd. is the 14001th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 445.73 M
Revenue (ttm) 211.65 M
Net Income (ttm) 34.07 M
Shares Out 41.63 M
EPS (ttm) 0.82
Forward PE 11.96
Ex-Dividend Date March 28, 2025
Earnings Date May 8, 2025
Market Cap Chart
Data Updated: May 4, 2025

Shin Nippon Biomedical Laboratories, Ltd.'s yearly market capitalization.

Shin Nippon Biomedical Laboratories, Ltd. has seen its market value grow from ¥28.10 B to ¥65.15 B since 2020, representing a total increase of 131.85% and an annual compound growth rate (CAGR) of 21.41%.
Date Market Cap Change (%)
May 1, 2025 ¥65.15 B -6.18%
December 30, 2024 ¥69.44 B -1.77%
December 29, 2023 ¥70.69 B -24.87%
December 30, 2022 ¥94.09 B 59.15%
December 30, 2021 ¥59.12 B 110.37%
December 30, 2020 ¥28.10 B

Company Profile

About Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd. is a leading contract research organization (CRO) operating in Japan and internationally. Founded in 1957 and headquartered in Kagoshima, Japan, the company specializes in transactional research and medipolis businesses.

Core Services

  • Non-Clinical Studies: Comprehensive testing including toxicity, genotoxicity, carcinogenicity, pharmacokinetics, and safety pharmacology studies.
  • Clinical Trial Support: Services such as protocol creation, investigator brochure preparation, monitoring, data management, and regulatory consulting.
  • Translational Research: Development of vaccines, therapeutic drugs, antibody/nucleic acid/peptide drugs, gene therapy, and regenerative medicines.
  • Site & Clinical Management: Site management organization (SMO) and clinical contract research organization (CRO) services.

Additional Business Ventures

  • Geothermal power generation operations.
  • Hotel accommodation and wellbeing businesses.
  • Support services including cleaning, clerical work, and welfare services.
Frequently Asked Questions

As of May 4, 2025, Shin Nippon Biomedical Laboratories, Ltd. (including the parent company, if applicable) has an estimated market capitalization of $445.73 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Shin Nippon Biomedical Laboratories, Ltd. global market capitalization ranking is approximately 14001 as of May 4, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Japan
Founded 1957
IPO Date n/a
Employees 1,341
CEO Ryoichi Nagata
Sector Healthcare
Industry Medical - Diagnostics & Research
Address 2438 Miyanoura-cho
Kagoshima, 891-1394
Japan
People Also Watch
TYO-4544
19.27 0.77%
TYO-4694
20.20 0.77%
NSE-SURAKSHA
3.53 0.77%
TYO-4671
16.06 0.77%